Anzeige
Mehr »
Dienstag, 09.06.2026 - Börsentäglich über 12.000 News
Pentagon in Alarmbereitschaft? Dieser Rohstoff könnte jetzt Gold in den Schatten stellen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CS50 | ISIN: BE0974386188 | Ticker-Symbol: 86C
Tradegate
08.06.26 | 16:56
3,120 Euro
+1,13 % +0,035
Branche
Chemie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOTALYS NV Chart 1 Jahr
5-Tage-Chart
BIOTALYS NV 5-Tage-Chart
RealtimeGeldBriefZeit
3,0453,08520:20
3,0403,08020:20
GlobeNewswire (Europe)
843 Leser
Artikel bewerten:
(2)

Biotalys NV: Biotalys Announces New Dates for the Publication of its 2025 Annual Report and for its Annual Shareholders Meeting

Update on the further financing of the company

Ghent, BELGIUM, March 24, 2026 (GLOBE NEWSWIRE) -- Press release - regulated information

Biotalys (Euronext - BTLS), an Agricultural Technology (AgTech) company developing protein-based biocontrol solutions for sustainable crop protection, today announces that it will publish its annual report and financial results for the full year of 2025 on Wednesday, 29 April 2026 at 07:00 CEST.

This new date allows the company to take the recently announced changes at board and management level and the intended reorganisation of the company into account in the reporting process and to ensure that all relevant information is prepared with the appropriate oversight and quality.

The company has a cash runway until end of May 2026 and confirms it is in ongoing discussions with existing and new investors to obtain additional financing to support its operations in going concern. While no binding financing proposals are yet obtained, the company currently believes that the updated timeline will allow sufficient time to progress these discussions, ensuring that the annual report and financial figures correctly reflect a more advanced status thereof.

Webcast and Conference Call
In addition to the publication of its results, management will host a webcast and conference call followed by a Q&A session, conducted in English. The webcast will be held on Wednesday, 29 April 2026 at 15:00 CEST / 14:00 GMT / 09:00 AM ET and can be accessed via the following link:
https://edge.media-server.com/mmc/p/f4cri5hy.

To ask live questions to the management, please register for the conference call via the following link: https://register-conf.media-server.com/register/BI5166f65ce5be4a02bf5d80a0bc047aaa.

A recording of the webcast will be available after the event on the Biotalys investor website: https://www.biotalys.com/investors/financial-information.

Annual General Shareholders Meeting (AGM)

Shareholders, holders of subscription rights and all other persons entitled to participate in its shareholders meetings, will be invited to the ordinary general shareholders meeting that will be held on Friday, 29 May 2026, 10.00 CEST at the company's headquarters.

About Biotalys

Biotalys is an Agricultural Technology (AgTech) company developing precision biocontrol solutions based on proteins for the protection of crops in both the pre- and post-harvest markets. The company provides novel solutions that bridge the efficacy and scale of chemistry with the environmental advantages of biological solutions. Based on its novel AGROBODY technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.

For further information, please contact:

Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: IR@biotalys.com

Important Notice

Biotalys, its business, prospects and financial position remain exposed and subject to risks and uncertainties. A description of and reference to these risks and uncertainties can be found in the annual report on the consolidated annual accounts published on the company's website.

Biotalys does not have sufficient working capital to cover the working capital needs for a period of at least 12 months as of the date hereof and only has a cash runway until end of May 2026. The company will require additional funds beyond this period to meet its capital and expenditure needs and ensure its going concern even if the intended restructuring of the company would be completed (see Biotalys' press release of 9 February 2026).

The company is in discussion with current and new investors and continues to evaluate financing options it being noted that, on the date hereof, no binding financing options or proposals are obtained by the company. Such financing might eventually not be available or if available, might result in an important dilution of existing shareholders or, in general, not be available on commercially favourable terms.

This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'aim', 'believe', 'estimate', 'anticipate', 'expect', 'intend', "have the potential", 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' 2 or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. Biotalys' actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.

Attachments

  • Biotalys_Updated Notice of Publication of its 2025 Annual Report and of Annual Shareholders Meeting_24 March 2026
  • Biotalys maakt nieuwe data bekend voor de publicatie van haar jaarverslag 2025 en voor haar jaarlijkse aandeelhoudersvergadering_24 maart 2026

© 2026 GlobeNewswire (Europe)
Software vor dem Comeback – diese 5 Aktien könnten durchstarten!
Während Halbleiter- und KI-Infrastrukturwerte von einem Hoch zum nächsten jagen, wurden viele Software-Aktien in den vergangenen Monaten regelrecht aus den Depots gedrängt. Die Angst vor Disruption hat Investoren zu einem radikalen Strategiewechsel veranlasst – mit der Folge, dass zahlreiche Qualitätsunternehmen heute auf Mehrjahrestiefs notieren.

Doch genau hier entsteht eine seltene Chance. Denn während die Bewertungen im Halbleitersektor inzwischen auf ambitionierten Niveaus liegen, ist der Bewertungsabschlag bei Software-Titeln so hoch wie seit Jahren nicht mehr. Gleichzeitig liefern viele Unternehmen weiterhin starke Wachstumszahlen und integrieren KI erfolgreich in ihre Geschäftsmodelle. Die Diskrepanz zwischen Kursentwicklung und operativer Stärke könnte sich schon bald auflösen.

Für Anleger bedeutet das: antizyklisch denken und gezielt zugreifen, bevor der Markt dreht. Denn erste technische Signale deuten darauf hin, dass sich die Trendwende bereits anbahnt.

In unserem aktuellen Spezialreport stellen wir fünf Software-Aktien vor, die besonders aussichtsreich positioniert sind – mit starker Marktstellung, attraktiver Bewertung und hohem Aufholpotenzial.

Jetzt den kostenlosen Report sichern – bevor der Software-Rebound Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.